Preventing dangerous blood acid buildup when using SGLT2 inhibitors for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether using a dual continuous glucose and ketone monitor can help people with type 1 diabetes safely take a class of drugs called SGLT2 inhibitors, which may improve blood sugar control but can increase the risk of diabetic ketoacidosis (DKA). By closely monitoring changes in glucose and ketone levels, the study aims to prevent dangerous episodes while benefiting from the drug's effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old and have a diagnosis of type 1 diabetes for at least 3 months.
- You use an insulin pump (automated insulin delivery) or take multiple daily insulin injections.
- Your most recent kidney function test (eGFR) was 25 or higher (within the past year).
- Your A1C level (average blood sugar over 2-3 months) is between 7% and 9%.
- You have never taken a medicine called an SGLT2 inhibitor (e.g., canagliflozin, dapagliflozin, empagliflozin).
- You can wear a device that checks your glucose and ketone levels continuously, and have access to a smartphone or computer with internet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding a non-insulin medication can lower the amount of insulin needed while improving heart and metabolic health in people with type 1 diabetes. It may also help understand how this approach works in people with a genetic form of diabetes (GCK-MODY).
This study tests different ways to monitor ketones (substances that can build up dangerously when your body lacks insulin) to lower the risk of diabetic ketoacidosis (DKA) in people with type 1 diabetes who also take SGLT-2 inhibitors (a type of diabetes drug). You'll wear a small sensor and follow a meal plan with carbs.
This study tests whether a medication called an SGLT2 inhibitor is safe for people with type 1 diabetes. It aims to lower blood sugar without increasing the risk of dangerous complications.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This study looks at how SGLT2 inhibitor medications (a type of diabetes drug) protect the kidneys in people with type 2 diabetes and chronic kidney disease. Researchers will use MRI scans to understand the protective effects, which could help improve future treatments.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.